To systematically evaluate the clinical efficacy and safety of dipyridamole combined with immunoglobulin and aspirin in the treatment of Kawasaki disease (KD) in children.
Approach:
Study Design: A meta-analysis of randomized controlled trials (RCTs) comparing dipyridamole combined with immunoglobulin and aspirin against immunoglobulin combined with aspirin.
Data Sources: Search conducted in multiple databases including PubMed, CBM, CNKI, Wanfang, and VIP up to February 2026.
Inclusion Criteria: RCTs involving pediatric patients diagnosed with KD, under 8 years of age, without prior treatment.
Outcome Measures: Primary outcomes included clinical efficacy, time for symptom improvement, laboratory indicators (CRP, ESR, PLT, CAL, FIB), and incidence of adverse reactions.
Key Findings:
The total effective rate in the observation group (dipyridamole + immunoglobulin + aspirin) was significantly higher than in the control group (immunoglobulin + aspirin).
Clinical symptom improvement time, CRP, ESR, PLT, CAL, and FIB levels were significantly lower in the observation group.
No significant difference in the incidence of adverse reactions between the two groups.
Interpretation:
The combination of dipyridamole with immunoglobulin and aspirin shows superior efficacy in treating Kawasaki disease in children compared to the standard treatment.
Limitations:
The study only included RCTs, which may limit the generalizability of the findings.
Potential publication bias due to the inclusion of only published studies.
Conclusion:
Dipyridamole combined with immunoglobulin and aspirin is more effective than immunoglobulin combined with aspirin in treating Kawasaki disease in children, with comparable safety.
